Close Menu

NEW YORK (GenomeWeb) – Indi Molecular is collaborating with GE Healthcare on Positron Emission Tomography (PET) imaging agents aimed at guiding treatment with cancer immunotherapies.

The companies are developing PET tracers targeting the cell surface protein CD8, allowing for PET imaging-based detection of cytotoxic T lymphocyctes, which have been shown to be predictive of immunotherapy response, said Albert Luderer, CEO and co-founder of Indi Molecular.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
17

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.